Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.769
  • Today's Change-0.028 / -3.45%
  • Shares traded5.03m
  • 1 Year change-31.09%
  • Beta0.7212
Data delayed at least 15 minutes, as of Oct 31 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

  • Revenue in EUR (TTM)263.24m
  • Net income in EUR-16.42m
  • Incorporated1988
  • Employees415.00
  • Location
    Pharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
  • Phone+31 715247400
  • Fax+31 715247445
  • Websitehttps://www.pharming.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Shenqi Pharmactcl Inv Mgt CoLtd290.71m7.78m528.71m1.43k64.991.85--1.820.12370.12374.364.340.70025.485.731,574,780.001.95-0.60022.48-0.741745.8956.642.79-0.91282.5023.180.1488---2.004.7917.41-11.68-25.97--
CorMedix Inc742.56k-48.93m534.73m82.00--12.03--720.11-0.9262-0.92620.01410.83550.014----9,830.73-92.57-54.84-110.35-62.32-64.796.18-6,589.09-18,323.424.43--0.00---100.00---56.02--46.27--
Pharmanutra SpA106.64m14.50m538.26m112.0036.869.7530.405.051.511.5111.095.700.98270.62574.401,015,648.0013.3618.3917.7624.8095.6396.3613.5917.771.8441.910.330552.5121.1316.51-14.738.4475.7111.20
Pharming Group N.V.263.24m-16.42m538.46m415.00--2.59--2.05-0.0258-0.02580.42730.30660.6630.5246.44634,305.70-4.145.26-4.996.6389.3989.41-6.249.262.76-4.840.3601--19.309.01-177.14---13.04--
Canopy Growth Corp190.21m-399.05m544.37m1.03k--1.04--2.86-7.53-9.583.556.580.16521.754.22279,008.80-34.65-26.08-41.36-28.6731.062.59-209.79-333.291.64-0.29570.5392---10.835.5984.29---64.60--
Shanghai OPM Biosciences Co Ltd34.37m5.22m546.63m285.00104.921.97--15.900.35070.35072.3118.700.11652.102.75931,523.801.734.341.784.6557.6658.3114.8623.4020.08--0.032845.38-17.4148.34-48.72--6.09--
ScinoPharm Taiwan Ltd98.82m11.62m548.17m1.01k47.301.8321.745.550.50840.50844.3313.120.28711.276.63--3.372.333.692.5138.8941.0911.769.105.00--0.0592109.25-2.39-2.00-18.73-8.3116.90-9.35
Chengdu Olymvax Biopharmaceuticals Inc63.33m-5.04m550.73m471.00--4.83--8.70-0.096-0.0961.212.170.3110.36770.99841,038,635.00-2.913.17-4.184.6893.5993.00-9.357.441.65-5.250.2869.82-9.3845.40-33.94--56.47--
Supriya Lifescience Ltd68.46m17.25m551.33m448.0032.005.5628.798.0519.5419.5477.55112.560.67372.016.5613,950,510.0016.9819.0818.3824.0466.8157.1225.2024.714.05111.460.0062.8823.7415.4732.5624.7583.79--
Data as of Oct 31 2024. Currency figures normalised to Pharming Group NV's reporting currency: Euro EUR

Institutional shareholders

12.40%Per cent of shares held by top holders
HolderShares% Held
RTW Investments LPas of 18 Jan 202420.03m2.95%
Acadian Asset Management LLCas of 23 Mar 202318.81m2.77%
BlackRock Fund Advisorsas of 03 Oct 202410.61m1.56%
DWS Investment GmbHas of 06 Feb 20249.95m1.47%
Dimensional Fund Advisors LPas of 03 Oct 20248.44m1.24%
Norges Bank Investment Managementas of 30 Jun 20245.00m0.74%
Healthinvest Partners ABas of 31 Dec 20233.95m0.58%
BlackRock Advisors (UK) Ltd.as of 03 Oct 20242.79m0.41%
Medical Strategy GmbHas of 28 Jun 20242.46m0.36%
KBC Asset Management NVas of 30 Jun 20242.10m0.31%
More ▼
Data from 28 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.